Access to healthcare in another member state
A cross-party group of MEPs have submitted aon barriers imposed by the Directive 2011/24/EU on the application of patients' rights in cross-border healthcare for patient access to gene therapies and other advanced therapy medicinal products for severe and rare genetic diseases. The MEPs stated that the burden of upfront payments, the complex and often opaque approval process and varying approval timelines across the EU all act as barriers to patients.
In its response, the EC stated that its ongoing evaluation of the Directive will assess to what extent it has contributed to removing obstacles to access to healthcare in another member state and what factors have hindered this. The EC will decide on any follow-up action once its consultation and evaluation are completed in the second quarter of 2022.